From IPEX syndrome to FOXP3 mutation: A lesson on immune dysregulation

Annals of the New York Academy of Sciences

Volumn 1417, Issue 1, 2016, Pages 5-22

  Bacchetta, Rosa ^a   Barzaghi, Federica ^b   Roncarolo, Maria Grazia ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SAN RAFFAELE SCIENTIFIC INSTITUTE   (Italy)

Author keywords

Autoimmune enteropathy; FOXP3; HSCT; IPEX; Neonatal diabetes; Primary immunodeficiency; Treg

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; TRANSCRIPTION FACTOR FOXP3; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN;

B LYMPHOCYTE; CLINICAL FEATURE; EFFECTOR CELL; FAMILY HISTORY; GENE MUTATION; GENE STRUCTURE; GENE THERAPY; GENETIC REGULATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNE DYSREGULATION; IMMUNOGENETICS; IMMUNOSUPPRESSIVE TREATMENT; IPEX SYNDROME; LABORATORY TEST; NONHUMAN; PERINATAL PERIOD; REGULATORY T LYMPHOCYTE; REVIEW; SUBSTITUTION THERAPY; BIOLOGICAL MODEL; CHEMISTRY; DIARRHEA; FEMALE; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; IMMUNOPATHOLOGY; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MUTATION; NEWBORN; PHENOTYPE; PREGNANCY; PROMOTER REGION; PROTEIN DOMAIN; REGULATORY SEQUENCE; T LYMPHOCYTE SUBPOPULATION; X CHROMOSOME LINKED DISORDER;

B-LYMPHOCYTES; DIABETES MELLITUS, TYPE 1; DIARRHEA; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION; GENETIC DISEASES, X-LINKED; GENETIC THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNE SYSTEM DISEASES; IMMUNOSUPPRESSION; INFANT, NEWBORN; MALE; MODELS, GENETIC; MODELS, IMMUNOLOGICAL; MUTATION; PHENOTYPE; PREGNANCY; PROMOTER REGIONS, GENETIC; PROTEIN DOMAINS; REGULATORY SEQUENCES, NUCLEIC ACID; T-LYMPHOCYTE SUBSETS;

EID: 84959420152     PISSN: 00778923     EISSN: 17496632     Source Type: Journal    
DOI: 10.1111/nyas.13011     Document Type: Review

References (156)

1. Powell, B.R., N.R. Buist & P. Stenzel. 1982. An X-linked syndrome of diarrhea, polyendocrinopathy, and fatal infection in infancy. J. Pediatr. 100: 731–737.
2. Chatila, T.A., F. Blaeser, N. Ho, et al. 2000. JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic disregulation syndrome. J. Clin. Invest. 106: R75–R81.
3. Godfrey, V.L., J.E. Wilkinson & L.B. Russell. 1991. X-linked lymphoreticular disease in the scurfy (sf) mutant mouse. Am. J. Pathol. 138: 1379–1387.
4. Brunkow, M.E., E.W. Jeffery, K.A. Hjerrild, et al. 2001. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat. Genet. 27: 68–73.
5. Bennett, C.L., J. Christie, F. Ramsdell, et al. 2001. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat. Genet. 27: 20–21.
6. Wildin, R.S., F. Ramsdell, J. Peake, et al. 2001. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat. Genet. 27: 18–20.
7. Kanangat, S., P. Blair, R. Reddy, et al. 1996. Disease in the scurfy (sf) mouse is associated with overexpression of cytokine genes. Eur. J. Immunol. 26: 161–165.
8. – T cells are the effector cells in disease pathogenesis in the scurfy (sf) mouse. J. Immunol. 153: 3764–3774.
9. Khattri, R., D. Kasprowicz, T. Cox, et al. 2001. The amount of scurfin protein determines peripheral T cell number and responsiveness. J. Immunol. 167: 6312–6320.
10. + T regulatory cells. Nat. Immunol. 4: 337–342.
11. Sakaguchi, S., N. Sakaguchi, M. Asano, M. Itoh & M. Toda. 1995. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155: 1151–1164.
12. Gratz, I.K., M.D. Rosenblum & A.K. Abbas. 2013. The life of regulatory T cells. Ann. N. Y. Acad. Sci. 1283: 8–12.
13. Gavin, M.A., J.P. Rasmussen, J.D. Fontenot, et al. 2007. Foxp3-dependent programme of regulatory T-cell differentiation. Nature 445: 771–775.
14. Zhou, X., L.T. Jeker, B.T. Fife, et al. 2008. Selective miRNA disruption in T reg cells leads to uncontrolled autoimmunity. J. Exp. Med. 205: 1983–1991.
15. Abbas, A.K., C. Benoist, J.A. Bluestone, et al. 2013. Regulatory T cells: recommendations to simplify the nomenclature. Nat. Immunol. 14: 307–308.
16. Ziegler, S.F. 2006. FOXP3: of mice and men. Annu. Rev. Immunol. 24: 209–226.
17. Magg, T., J. Mannert, J.W. Ellwart, I. Schmid &M.H. Albert. 2012. Subcellular localization of FOXP3 in human regulatory and nonregulatory T cells. Eur. J. Immunol. 42: 1627– 1638.
18. Lal, G. & J.S. Bromberg. 2009. Epigenetic mechanisms of regulation of Foxp3 expression. Blood 114: 3727–3735.
19. Kitagawa, Y., N. Ohkura & S. Sakaguchi. 2015. Epigenetic control of thymic Treg-cell development. Eur. J. Immunol. 45: 11–16.
20. Ohkura, N., Y. Kitagawa & S. Sakaguchi. 2013. Development and maintenance of regulatory T cells. Immunity 38: 414–423.
21. Ohkura, N., M. Hamaguchi, H. Morikawa, et al. 2012. T cell receptor stimulation-induced epigenetic changes and Foxp3 expression are independent and complementary events required for Treg cell development. Immunity 37: 785–799.
22. Zheng, Y., S. Josefowicz, A. Chaudhry, X.P. Peng, K. Forbush & A.Y. Rudensky. 2010. Role of conserved noncoding DNA elements in the Foxp3 gene in regulatory T-cell fate. Nature 463: 808–812.
23. Janson, P.C., M.E. Winerdal, P. Marits, M. Thorn, R. Ohlsson & O. Winqvist. 2008. FOXP3 promoter demethylation reveals the committed Treg population in humans. PLoS One 3: e1612.
24. Liu, B., S. Tahk, K.M. Yee, G. Fan & K. Shuai. 2010. The lig-ase PIAS1 restricts natural regulatory T cell differentiation by epigenetic repression. Science 330: 521–525.
25. Ouyang, W., W. Liao, C.T. Luo, et al. 2012. Novel Foxo1-dependent transcriptional programs control T(reg) cell function. Nature 491: 554–559.
26. Tone, Y., K. Furuuchi, Y. Kojima, M.L. Tykocinski, M.I. Greene & M. Tone. 2008. Smad3 and NFAT cooperate to induce Foxp3 expression through its enhancer. Nat. Immunol. 9: 194–202.
27. Josefowicz, S.Z., R.E. Niec, H.Y. Kim, et al. 2012. Extrathymically generated regulatory T cells control mucosal TH2 inflammation. Nature 482: 395–399.
28. Baron, U., S. Floess, G. Wieczorek, et al. 2007. DNA demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FOXP3(+) conventional T cells. Eur. J. Immunol. 37: 2378–2389.
29. Huehn, J., J.K. Polansky & A. Hamann. 2009. Epigenetic control of FOXP3 expression: the key to a stable regulatory T-cell lineage? Nat. Rev. Immunol. 9: 83–89.
30. Toker, A., D. Engelbert, G. Garg, et al. 2013. Active demethylation of the Foxp3 locus leads to the generation of stable regulatory T cells within the thymus. J. Immunol. 190: 3180–3188.
31. Feng, Y., A. Arvey, T. Chinen, J. van der Veeken, G. Gasteiger & A.Y. Rudensky. 2014. Control of the inheritance of regulatory T cell identity by a cis element in the Foxp3 locus. Cell 158: 749–763.
32. Rudra, D., T. Egawa, M.M. Chong, P. Treuting, D.R. Littman & A.Y. Rudensky. 2009. Runx–CBFbeta complexes control expression of the transcription factor Foxp3 in regulatory T cells. Nat. Immunol. 10: 1170–1177.
33. Li, X., Y. Liang, M. LeBlanc, C. Benner & Y. Zheng. 2014. Function of a Foxp3 cis-element in protecting regulatory T cell identity. Cell 158: 734–748.
34. Vang, K.B., J. Yang, A.J. Pagan, et al. 2010. Cutting edge: CD28 and c-Rel-dependent pathways initiate regulatory T cell development. J. Immunol. 184: 4074–4077.
35. + regulatory T cells. Semin. Immunol. 27: 10–18.
36. Zheng, Y., S.Z. Josefowicz, A. Kas, T.T. Chu, M.A. Gavin & A.Y. Rudensky. 2007. Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells. Nature 445: 936–940.
37. + regulatory T cells. Science 325: 1142–1146.
38. Li, B., A. Samanta, X. Song, et al. 2007. FOXP3 interactions with histone acetyltransferase and class II histone deacety-lases are required for repression. Proc. Natl. Acad. Sci. U.S.A. 104: 4571–4576.
39. Zhou, L., J.E. Lopes, M.M. Chong, et al. 2008. TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function. Nature 453: 236– 240.
40. Du, J., C. Huang, B. Zhou & S.F. Ziegler. 2008. Isoform-specific inhibition of ROR alpha-mediated transcriptional activation by human FOXP3. J. Immunol. 180: 4785–4792.
41. Wu, Y., M. Borde, V. Heissmeyer, et al. 2006. FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell 126: 375–387.
42. Ono, M., H. Yaguchi, N. Ohkura, et al. 2007. Foxp3 controls regulatory T-cell function by interacting with AML1/Runx1. Nature 446: 685–689.
43. Rudra, D., P. deRoos, A. Chaudhry, et al. 2012. Transcription factor Foxp3 and its protein partners form a complex regulatory network. Nat. Immunol. 13: 1010–1019.
44. Barzaghi, F., L. Passerini & R. Bacchetta. 2012. Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome: a paradigm of immunodeficiency with autoimmunity. Front. Immunol. 3: 211.
45. d’Hennezel, E., K. Bin Dhuban, T. Torgerson & C.A. Pic-cirillo. 2012. The immunogenetics of immune dysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome. J. Med. Genet. 49: 291–302.
46. Sheikine, Y., C.B. Woda, P.Y. Lee, et al. 2015. Renal involvement in the immunodysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) disorder. Pediatr. Nephrol. 30: 1197–1202.
47. Park, E., H.J. Chang, J.I. Shin, et al. 2015. Familial IPEX syndrome: different glomerulopathy in two siblings. Pediatr. Int. 57: e59–e61.
48. Baris, S., I. Schulze, A. Ozen, et al. 2014. Clinical heterogeneity of immunodysregulation, polyendocrinopathy, enteropathy, X-linked: pulmonary involvement as a nonclassical disease manifestation. J. Clin. Immunol. 34: 601– 606.
49. Bis, S., S.M. Maguiness, S.E. Gellis, et al. 2015. Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome associated with neonatal epidermolysis bullosa acquisita. Pediatr. Dermatol. 32: e74–e77.
50. Savova, R., M. Arshinkova, J. Houghton, et al. 2014. Clinical case of immune dysregulation, polyendocrinopaty, enteropathy, X-linked (IPEX) syndrome with severe immune deficiency and late onset of endocrinopathy and enteropathy. Case Rep. Med. 2014: 564926.
51. Nademi, Z., M. Slatter, E. Gambineri, et al. 2014. Single centre experience of haematopoietic SCT for patients with immunodysregulation, polyendocrinopathy, enteropathy, X-linked syndrome. Bone Marrow Transplant. 49: 310–312.
52. Xavier-da-Silva, M.M., C.A. Moreira-Filho, E. Suzuki, F. Patricio, A. Coutinho & M. Carneiro-Sampaio. 2015. Fetal-onset IPEX: report of two families and review of literature. Clin. Immunol. 156: 131–140.
53. Vasiljevic, A., B. Poreau, R. Bouvier, et al. 2015. Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome and recurrent intrauterine fetal death. Lancet 385: 2120.
54. Reichert, S.L., E.M. McKay & J.S. Moldenhauer. 2016. Identification of a novel nonsense mutation in the FOXP3 gene in a fetus with hydrops-Expanding the phenotype of IPEX syndrome. Am. J. Med. Genet. A 170: 226–232.
55. Rae, W., Y. Gao, D. Bunyan, et al. 2015. A novel FOXP3 mutation causing fetal akinesia and recurrent male miscarriages. Clin. Immunol. 161: 284–285.
56. Nieves, D.S., R.P. Phipps, S.J. Pollock, et al. 2004. Dermatologic and immunologic findings in the immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome. Arch. Dermatol. 140: 466–472.
57. + regulatory T cells and their impairment in patients with FOXP3 gene mutations. Clin. Immunol. 125: 237–246.
58. Taddio, A., E. Faleschini, E. Valencic, et al. 2007. Medium-term survival without haematopoietic stem cell transplantation in a case of IPEX: insights into nutritional and immunosuppressive therapy. Eur. J. Pediatr. 166: 1195– 1197.
59. Ferguson, P.J., S.H. Blanton, F.T. Saulsbury, et al. 2000. Manifestations and linkage analysis in X-linked autoimmunity-immunodeficiency syndrome. Am. J. Med. Genet. 90: 390–397.
60. Wildin, R.S., S. Smyk-Pearson & A.H. Filipovich. 2002. Clinical and molecular features of the immunodysregu-lation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome. J. Med. Genet. 39: 537–545.
61. Levy-Lahad, E. & R.S. Wildin. 2001. Neonatal diabetes mellitus, enteropathy, thrombocytopenia, and endocrinopathy: further evidence for an X-linked lethal syndrome. J. Pediatr. 138: 577–580.
62. Gambineri, E., L. Perroni, L. Passerini, et al. 2008. Clinical and molecular profile of a new series of patients with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome: inconsistent correlation between forkhead box protein 3 expression and disease severity. J. Allergy Clin. Immunol. 122: 1105–1112.e1.
63. Gavin, M.A., T.R. Torgerson, E. Houston, et al. 2006. Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development. Proc. Natl. Acad. Sci. U.S.A. 103: 6659–6664.
64. Burroughs, L.M., T.R. Torgerson, R. Storb, et al. 2010. Stable hematopoietic cell engraftment after low-intensity nonmyeloablative conditioning in patients with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome. J. Allergy Clin. Immunol. 126: 1000–1005.
65. An, Y.F., F. Xu, M. Wang, Z.Y. Zhang & X.D. Zhao. 2011. Clinical and molecular characteristics of immunodysregulation, polyendocrinopathy, enteropathy, X-linked syndrome in China. Scand. J. Immunol. 74: 304–309.
66. Passerini, L., S. Olek, S. Di Nunzio, et al. 2011. Forkhead box protein 3 (FOXP3) mutations lead to increased TH17 cell numbers and regulatory T-cell instability. J. Allergy Clin. Immunol. 128: 1376–1379.e1.
67. Bennett, C.L., M.E. Brunkow, F. Ramsdell, et al. 2001. A rare polyadenylation signal mutation of the FOXP3 gene (AAUAAA→AAUGAA) leads to the IPEX syndrome. Immunogenetics 53: 435–439.
68. Tsuda, M., T.R. Torgerson, C. Selmi, et al. 2010. The spectrum of autoantibodies in IPEX syndrome is broad and includes anti-mitochondrial autoantibodies. J. Autoimmun. 35: 265–268.
69. Dorsey, M.J., A. Petrovic, M.R. Morrow, L.J. Dishaw & J.W. Sleasman. 2009. FOXP3 expression following bone marrow transplantation for IPEX syndrome after reduced-intensity conditioning. Immunol. Res. 44: 179–184.
70. Patey-Mariaud de Serre, N., D. Canioni, S. Ganousse, et al. 2009. Digestive histopathological presentation of IPEX syndrome. Mod. Pathol. 22: 95–102.
71. + Tregs. J. Clin. Invest. 115: 3276–3284.
72. Barzaghi, F., L. Passerini, E. Gambineri, et al. 2012. Demethylation analysis of the FOXP3 locus shows quantitative defects of regulatory T cells in IPEX-like syndrome. J. Autoimmun. 38: 49–58.
73. Bacchetta, R., L. Passerini, E. Gambineri, et al. 2006. Defective regulatory and effector T cell functions in patients with FOXP3 mutations. J. Clin. Invest. 116: 1713–1722.
74. d’Hennezel, E., M. Ben-Shoshan, H.D. Ochs, et al. 2009. FOXP3 forkhead domain mutation and regulatory T cells in the IPEX syndrome. N. Engl. J. Med. 361: 1710–1713.
75. Moes, N., F. Rieux-Laucat, B. Begue, et al. 2010. Reduced expression of FOXP3 and regulatory T-cell function in severe forms of early-onset autoimmune enteropathy. Gastroenterology 139: 770–778.
76. Shevach, E.M. & A.M. Thornton. 2014. tTregs, pTregs, and iTregs: similarities and differences. Immunol. Rev. 259: 88–102.
77. Yadav, M., S. Stephan & J.A. Bluestone. 2013. Peripherally induced tregs: role in immune homeostasis and autoimmunity. Front. Immunol. 4: 232.
78. Wan, Y.Y. & R.A. Flavell. 2007. Regulatory T-cell functions are subverted and converted owing to attenuated Foxp3 expression. Nature 445: 766–770.
79. Seddiki, N., B. Santner-Nanan, J. Martinson, et al. 2006. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J. Exp. Med. 203: 1693–1700.
80. + regulatory T cells express lower levels of the IL-7 receptor alpha chain (CD127), allowing consistent identification and sorting of live cells. J. Immunol. Methods 319: 41–52.
81. Yu, X., K. Harden, L.C. Gonzalez, et al. 2009. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat. Immunol. 10: 48–57.
82. + regulatory T cell function. Science 322: 271–275.
83. + T regulatory cells. J. Immunol. 184: 3433– 3441.
84. + Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 110: 1225–1232.
85. Maliszewski, C.R., G.J. Delespesse, M.A. Schoenborn, et al. 1994. The CD39 lymphoid cell activation antigen. Molecular cloning and structural characterization. J. Immunol. 153: 3574–3583.
86. Hamann, A., K. Klugewitz, F. Austrup & D. Jablonski-Westrich. 2000. Activation induces rapid and profound alterations in the trafficking of T cells. Eur. J. Immunol. 30: 3207–3218.
87. Deaglio, S., K.M. Dwyer, W. Gao, et al. 2007. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J. Exp. Med. 204: 1257–1265.
88. Morikawa, H. & S. Sakaguchi. 2014. Genetic and epigenetic basis of Treg cell development and function: from a FoxP3-centered view to an epigenome-defined view of natural Treg cells. Immunol. Rev. 259: 192–205.
89. Amendola, M., L. Passerini, F. Pucci, B. Gentner, R. Bacchetta & L. Naldini. 2009. Regulated and multiple miRNA and siRNA delivery into primary cells by a lentiviral platform. Mol. Ther. 17: 1039– 1052.
90. McMurchy, A.N., J. Gillies, S.E. Allan, et al. 2010. Point mutants of forkhead box P3 that cause immune dysregulation, polyendocrinopathy, enteropathy, X-linked have diverse abilities to reprogram T cells into regulatory T cells. J. Allergy Clin. Immunol. 126: 1242–1251.
91. Bandukwala, H.S., Y. Wu, M. Feuerer, et al. 2011. Structure of a domain-swapped FOXP3 dimer on DNA and its function in regulatory T cells. Immunity 34: 479–491.
92. Allan, S.E., S.Q. Crome, N.K. Crellin, et al. 2007. Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int. Immunol. 19: 345–354.
93. + FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype. Blood 110: 2983–2990.
94. − effector T cells. Int. Immunol. 20: 421–431.
95. McMurchy, A.N., J. Gillies, M.C. Gizzi, et al. 2013. A novel function for FOXP3 in humans: intrinsic regulation of conventional T cells. Blood 121: 1265–1275.
96. Kinnunen, T., N. Chamberlain, H. Morbach, et al. 2013. Accumulation of peripheral autoreactive B cells in the absence of functional human regulatory T cells. Blood 121: 1595–1603.
97. Kobayashi, I., K. Imamura, M. Kubota, et al. 1999. Identification of an autoimmune enteropathy-related 75-kilodalton antigen. Gastroenterology 117: 823–830.
98. Gambineri, E., T.R. Torgerson & H.D. Ochs. 2003. Immune dysregulation, polyendocrinopathy, enteropathy, and X-linked inheritance (IPEX), a syndrome of systemic autoimmunity caused by mutations of FOXP3, a critical regulator of T-cell homeostasis. Curr. Opin. Rheumatol. 15: 430–435.
99. Patey-Mariaud de Serre, N., D. Canioni, S. Ganousse, et al. 2009. Digestive histopathological presentation of IPEX syndrome. Mod. Pathol. 22: 95–102.
100. Kobayashi, I., M. Kubota, M. Yamada, et al. 2011. Autoantibodies to villin occur frequently in IPEX, a severe immune dysregulation, syndrome caused by mutation of FOXP3. Clin. Immunol. 141: 83–89.
101. Kobayashi, I., K. Imamura, M. Yamada, et al. 1998. A 75-kD autoantigen recognized by sera from patients with X-linked autoimmune enteropathy associated with nephropathy. Clin. Exp. Immunol. 111: 527–531.
102. Lampasona, V., L. Passerini, F. Barzaghi, et al. 2013. Autoantibodies to harmonin and villin are diagnostic markers in children with IPEX syndrome. PLoS One 8: e78664.
103. Chida, N., I. Kobayashi, S. Takezaki, et al. 2015. Disease specificity of anti-tryptophan hydroxylase-1 and anti-AIE-75 autoantibodies in APECED and IPEX syndrome. Clin. Immunol. 156: 36–42.
104. Roncarolo, M.G., S. Gregori, R. Bacchetta & M. Battaglia. 2014. Tr1 cells and the counter-regulation of immunity: natural mechanisms and therapeutic applications. Curr. Top. Microbiol. Immunol. 380: 39–68.
105. Roers, A., L. Siewe, E. Strittmatter, et al. 2004. T cell-specific inactivation of the interleukin 10 gene in mice results in enhanced T cell responses but normal innate responses to lipopolysaccharide or skin irritation. J. Exp. Med. 200: 1289–1297.
106. − precursor cells in the absence of interleukin 10. Nat. Immunol. 8: 931–941.
107. + regulatory T cells. J. Immunol. 172: 5986–5993.
108. Passerini, L., S. Di Nunzio, S. Gregori, et al. 2011. Functional type 1 regulatory T cells develop regardless of FOXP3 mutations in patients with IPEX syndrome. Eur. J. Immunol. 41: 1120–1131.
109. Smith, E., S.A. Greeley, H. Ye, et al. 2014. Extremely early onset IPEX syndrome caused by a novel small exonic deletion in FOXP3. J. Pediatr. Gastroenterol. Nutr. doi: 10.1097/MPG.0000000000000554.
110. Burt, T.D. 2013. Fetal regulatory T cells and peripheral immune tolerance in utero: implications for development and disease. Am. J. Reprod. Immunol. 69: 346– 358.
111. Hashimura, Y., K. Nozu, H. Kanegane, et al. 2009. Minimal change nephrotic syndrome associated with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome. Pediatr. Nephrol. 24: 1181–1186.
112. Harbuz, R., J. Lespinasse, S. Boulet, et al. 2010. Identification of new FOXP3 mutations and prenatal diagnosis of IPEX syndrome. Prenat. Diagn. 30: 1072–1078.
113. Otsubo, K., H. Kanegane, Y. Kamachi, et al. 2011. Identification of FOXP3-negative regulatory T-like (CD4(+)CD25(+)CD127(low)) cells in patients with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome. Clin. Immunol. 141: 111–120.
114. Scaillon, M., S. Van Biervliet, P. Bontems, et al. 2009. Severe gastritis in an insulin-dependent child with an IPEX syndrome. J. Pediatr. Gastroenterol. Nutr. 49: 368–370.
115. Lucas, K.G., D. Ungar, M. Comito, M. Bayerl & B. Groh. 2007. Submyeloablative cord blood transplantation corrects clinical defects seen in IPEX syndrome. Bone Marrow Transplant. 39: 55–56.
116. Peake, J.E., R.B. McCrossin, G. Byrne & R. Shepherd. 1996. X-linked immune dysregulation, neonatal insulin dependent diabetes, and intractable diarrhoea. Arch. Dis. Child. Fetal Neonatal Ed. 74: F195–F199.
117. Baud, O., O. Goulet, D. Canioni, et al. 2001. Treatment of the immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) by allogeneic bone marrow transplantation. N. Engl. J. Med. 344: 1758–1762.
118. Rubio-Cabezas, O., J.A. Minton, R. Caswell, et al. 2009. Clinical heterogeneity in patients with FOXP3 mutations presenting with permanent neonatal diabetes. Diabetes Care 32: 111–116.
119. + with high proportion of memory T cells in an IPEX infant with a FOXP3 mutation in the forkhead domain. Scand. J. Immunol. 68: 85–91.
120. Owen, C.J., C.E. Jennings, H. Imrie, et al. 2003. Mutational analysis of the FOXP3 gene and evidence for genetic heterogeneity in the immunodysregulation, polyendocrinopathy, enteropathy syndrome. J. Clin. Endocrinol. Metab. 88: 6034–6039.
121. Ruemmele, F.M., N. Moes, N.P. de Serre, F. Rieux-Laucat & O. Goulet. 2008. Clinical and molecular aspects of autoimmune enteropathy and immune dysregulation, polyendocrinopathy autoimmune enteropathy X-linked syndrome. Curr. Opin. Gastroenterol. 24: 742–748.
122. Rao, A., N. Kamani, A. Filipovich, et al. 2007. Successful bone marrow transplantation for IPEX syndrome after reduced-intensity conditioning. Blood 109: 383–385.
123. De Benedetti, F., A. Insalaco, A. Diamanti, et al. 2006. Mechanistic associations of a mild phenotype of immunodysregulation, polyendocrinopathy, enteropathy, X-linked syndrome. Clin. Gastroenterol. Hepatol. 4: 653–659.
124. Halabi-Tawil, M., F.M. Ruemmele, S. Fraitag, et al. 2009. Cutaneous manifestations of immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome. Br. J. Dermatol. 160: 645–651.
125. McGinness, J.L., M.M. Bivens, K.E. Greer, J.W. Patterson & F.T. Saulsbury. 2006. Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) associated with pemphigoid nodularis: a case report and review of the literature. J. Am. Acad. Dermatol. 55: 143– 148.
126. McLucas, P., G.J. Fulchiero Jr., E. Fernandez, J.J. Miller & A.L. Zaenglein. 2007. Norwegian scabies mimicking ony-chomycosis and scalp dermatitis in a child with IPEX syndrome. J. Am. Acad. Dermatol. 56(2 Suppl): S48–S49.
127. Moudgil, A., P. Perriello, B. Loechelt, R. Przygodzki, W. Fitzerald & N. Kamani. 2007. Immunodysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome: an unusual cause of proteinuria in infancy. Pediatr. Nephrol. 22: 1799–1802.
128. Rodrigo, R., N. Atapattu & K.S. de Silva. 2013. IPEX syndrome with membrano-proliferative nephrotic syndrome. Ceylon Med. J. 58: 43–44.
129. Kobayashi, I., R. Shiari, M. Yamada, et al. 2001. Novel mutations of FOXP3 in two Japanese patients with immune dysregulation, polyendocrinopathy, enteropathy, X linked syndrome (IPEX). J. Med. Genet. 38: 874–876.
130. Myers, A.K., L. Perroni, C. Costigan & W. Reardon. 2006. Clinical and molecular findings in IPEX syndrome. Arch. Dis. Child. 91: 63–64.
131. Wang, J., X. Li, Z. Jia, et al. 2010. Reduced FOXP3 expression causes IPEX syndrome onset: an implication from an IPEX patient and his disease-free twin brother. Clin. Immunol. 137: 178–180.
132. Bae, K.W., B.E. Kim, J.H. Choi, et al. 2011. A novel mutation and unusual clinical features in a patient with immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome. Eur. J. Pediatr. 170: 1611–1615.
133. Bindl, L., T. Torgerson, L. Perroni, et al. 2005. Successful use of the new immune-suppressor sirolimus in IPEX (immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome). J. Pediatr. 147: 256–259.
134. Lopez, S.I., M. Ciocca, M. Oleastro, et al. 2011. Autoimmune hepatitis type 2 in a child with IPEX syndrome. J. Pediatr. Gastroenterol. Nutr. 53: 690–693.
135. Ochs, H.D. & T.R. Torgerson. 2007. Immune dysregulation, polyendocrinopathy, enteropathy, X-linked inheritance: model for autoaggression. Adv. Exp. Med. Biol. 601: 27–36.
136. Yong, P.L., P. Russo & K.E. Sullivan. 2008. Use of sirolimus in IPEX and IPEX-like children. J. Clin. Immunol. 28: 581– 587.
137. Zama, D., I. Cocchi, R. Masetti, et al. 2014. Late-onset of immunodysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) with intractable diarrhea. Ital. J. Pediatr. 40: 68.
138. Heltzer, M.L., J.K. Choi, H.D. Ochs, K.E. Sullivan, T.R. Torgerson & L.M. Ernst. 2007. A potential screening tool for IPEX syndrome. Pediatr. Dev. Pathol. 10: 98– 105.
139. Torgerson, T.R., A. Linane, N. Moes, et al. 2007. Severe food allergy as a variant of IPEX syndrome caused by a deletion in a noncoding region of the FOXP3 gene. Gastroenterology 132: 1705–1717.
140. Sayar, E., D.F. Uygun, A. Islek, et al. 2014. Langerhans cell histiocytosis in IPEX syndrome: possible role for natural regulatory T cells? Pediatr. Allergy Immunol. 25: 601– 603.
141. Huter, E.N., K. Natarajan, T.R. Torgerson, D.D. Glass & E.M. Shevach. 2010. Autoantibodies in scurfy mice and IPEX patients recognize keratin 14. J. Invest. Dermatol. 130: 1391–1399.
142. + regulatory T cells of both healthy subjects and type 1 diabetic patients. J. Immunol. 177: 8338–8347.
143. + T regulatory cells by activation-independent expression of FOXP3. Mol. Ther. 16: 194–202.
144. Mazzolari, E., C. Forino, M. Fontana, et al. 2005. A new case of IPEX receiving bone marrow transplantation. Bone Marrow Transplant. 35: 1033–1034.
145. Zhan, H., J. Sinclair, S. Adams, et al. 2008. Immune reconstitution and recovery of FOXP3 (forkhead box P3)-expressing T cells after transplantation for IPEX (immune dysregulation, polyendocrinopathy, enteropathy, X-linked) syndrome. Pediatrics 121: e998–e1002.
146. high FOXP3-positive T cells in IPEX syndrome after nonmyeloablative hematopoietic stem cell transplantation. Blood 113: 5689–5691.
147. Kasow, K.A., V.M. Morales-Tirado, D. Wichlan, et al. 2011. Therapeutic in vivo selection of thymic-derived natural T regulatory cells following non-myeloablative hematopoietic stem cell transplant for IPEX. Clin. Immunol. 141: 169–176.
148. Horino, S., Y. Sasahara, M. Sato, et al. 2014. Selective expansion of donor-derived regulatory T cells after allogeneic bone marrow transplantation in a patient with IPEX syndrome. Pediatr. Transplant. 18: E25–E30.
149. Kucuk, Z.Y., J.J. Bleesing, R. Marsh, K. Zhang, S. Davies & A.H. Filipovich. 2015. A challenging undertaking: stem cell transplantation for immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome. J. Allergy Clin. Immunol. pii: S0091-6749(15)01374-3. DOI: 10.1016/j.jaci.2015.09.030.
150. + CD25(hi) regulatory T cells of healthy female carriers of different FOXP3 mutations. Blood 114: 4138–4141.
151. Passerini, L., E. Rossi Mel, C. Sartirana, et al. 2013. CD4(+) T cells from IPEX patients convert into functional and stable regulatory T cells by FOXP3 gene transfer. Sci. Transl. Med. 5: 215ra174.
152. Aiuti, A., L. Biasco, S. Scaramuzza, et al. 2013. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott–Aldrich syndrome. Science 341: 1233151.
153. Aiuti, A., F. Cattaneo, S. Galimberti, et al. 2009. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N. Engl. J. Med. 360: 447–458.
154. Passerini, L., F.R. Santoni de Sio, M.G. Roncarolo & R. Bacchetta. 2014. Forkhead box P3: the peacekeeper of the immune system. Int. Rev. Immunol. 33: 129–145.
155. Kim, H., J.S. Kim. 2014. A guide to genome engineering with programmable nucleases. Nat. Rev. Genet. 15: 321– 334.
156. Hendel, A., R.O. Bak, J.T. Clark, et al. 2015. Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells. Nat. Biotechnol. 33: 985– 989.